By identifying the proteins that are increasingly O-GlcNAcylated in response to CDK9 inhibition, we can establish mechanistically, why combined inhibition of OGT and CDK9 is toxic to prostate cancer cells. The gene discussed is OGT; the disease is prostate cancer.